Analytical platforms and databases ranging from plant transcriptomics to metabolomics.

2010 ◽  
pp. 222-243
Author(s):  
T. Sakurai ◽  
K. Akiyama ◽  
K. Saito
Keyword(s):  
Author(s):  
Josep Miquel Bauça ◽  
Andrea Caballero ◽  
Carolina Gómez ◽  
Débora Martínez-Espartosa ◽  
Isabel García del Pino ◽  
...  

AbstractObjectivesThe stability of the analytes most commonly used in routine clinical practice has been the subject of intensive research, with varying and even conflicting results. Such is the case of alanine aminotransferase (ALT). The purpose of this study was to determine the stability of serum ALT according to different variables.MethodsA multicentric study was conducted in eight laboratories using serum samples with known initial catalytic concentrations of ALT within four different ranges, namely: <50 U/L (<0.83 μkat/L), 50–200 U/L (0.83–3.33 μkat/L), 200–400 U/L (3.33–6.67 μkat/L) and >400 U/L (>6.67 μkat/L). Samples were stored for seven days at two different temperatures using four experimental models and four laboratory analytical platforms. The respective stability equations were calculated by linear regression. A multivariate model was used to assess the influence of different variables.ResultsCatalytic concentrations of ALT decreased gradually over time. Temperature (−4%/day at room temperature vs. −1%/day under refrigeration) and the analytical platform had a significant impact, with Architect (Abbott) showing the greatest instability. Initial catalytic concentrations of ALT only had a slight impact on stability, whereas the experimental model had no impact at all.ConclusionsThe constant decrease in serum ALT is reduced when refrigerated. Scarcely studied variables were found to have a significant impact on ALT stability. This observation, added to a considerable inter-individual variability, makes larger studies necessary for the definition of stability equations.


Bioanalysis ◽  
2014 ◽  
Vol 6 (4) ◽  
pp. 563-581 ◽  
Author(s):  
Tiziana Cabras ◽  
Federica Iavarone ◽  
Barbara Manconi ◽  
Alessandra Olianas ◽  
Maria Teresa Sanna ◽  
...  

Vaccine ◽  
2014 ◽  
Vol 32 (35) ◽  
pp. 4365-4368 ◽  
Author(s):  
Céline Dutruel ◽  
Jelle Thole ◽  
Mark Geels ◽  
Hans-Joachim Mollenkopf ◽  
Tom Ottenhoff ◽  
...  

Metabolites ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 630
Author(s):  
Daniela Madama ◽  
Rosana Martins ◽  
Ana S. Pires ◽  
Maria F. Botelho ◽  
Marco G. Alves ◽  
...  

Lung cancer continues to be a significant burden worldwide and remains the leading cause of cancer-associated mortality. Two considerable challenges posed by this disease are the diagnosis of 61% of patients in advanced stages and the reduced five-year survival rate of around 4%. Noninvasively collected samples are gaining significant interest as new areas of knowledge are being sought and opened up. Metabolomics is one of these growing areas. In recent years, the use of metabolomics as a resource for the study of lung cancer has been growing. We conducted a systematic review of the literature from the past 10 years in order to identify some metabolites associated with lung cancer. More than 150 metabolites have been associated with lung cancer-altered metabolism. These were detected in different biological samples by different metabolomic analytical platforms. Some of the published results have been consistent, showing the presence/alteration of specific metabolites. However, there is a clear variability due to lack of a full clinical characterization of patients or standardized patients selection. In addition, few published studies have focused on the added value of the metabolomic profile as a means of predicting treatment response for lung cancer. This review reinforces the need for consistent and systematized studies, which will help make it possible to identify metabolic biomarkers and metabolic pathways responsible for the mechanisms that promote tumor progression, relapse and eventually resistance to therapy.


2019 ◽  
Vol 3 (1) ◽  
pp. 439-458 ◽  
Author(s):  
Maurice Mutro Nigo ◽  
Georgette Salieb-Beugelaar ◽  
Manuel Battegay ◽  
Peter Odermatt ◽  
Patrick Hunziker

Schistosomiasis is a neglected invasive worm disease with a huge disease burden in developing countries, particularly in children, and is seen increasingly in non-endemic regions through transfer by travellers, expatriates, and refugees. Undetected and untreated infections may be responsible for the persistence of transmission. Rapid and accurate diagnosis is the key to treatment and control. So far, parasitological detection methods remain the cornerstone of Schistosoma infection diagnosis in endemic regions, but conventional tests have limited sensitivity, in particular in low-grade infection. Recent advances contribute to improved detection in clinical and field settings. The recent progress in micro- and nanotechnologies opens a road by enabling the design of new miniaturized point-of-care devices and analytical platforms, which can be used for the rapid detection of these infections. This review starts with an overview of currently available laboratory tests and their performance and then discusses emerging rapid and micro/nanotechnologies-based tools. The epidemiological and clinical setting of testing is then discussed as an important determinant for the selection of the best analytical strategy in patients suspected to suffer from Schistosoma infection. Finally, it discusses the potential role of advanced technologies in the setting near to disease eradication is examined.


Bioanalysis ◽  
2014 ◽  
Vol 6 (22) ◽  
pp. 3051-3066 ◽  
Author(s):  
Lasse Jørgensen Cehofski ◽  
Nakul Mandal ◽  
Bent Honoré ◽  
Henrik Vorum
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document